Comparative Pharmacology
Head-to-head clinical analysis: SANDOSTATIN versus SANDOSTATIN LAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SANDOSTATIN versus SANDOSTATIN LAR.
SANDOSTATIN vs SANDOSTATIN LAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic octapeptide analog of somatostatin with longer half-life. Inhibits growth hormone (GH), glucagon, and insulin secretion. Reduces splanchnic blood flow and suppresses serotonin release from neuroendocrine tumors.
Synthetic octapeptide analog of somatostatin with greater metabolic stability and longer duration of action. Inhibits growth hormone (GH) secretion via binding to somatostatin receptors (SSTR2 and SSTR5) on pituitary somatotrophs. Also suppresses insulin-like growth factor-1 (IGF-1), glucagon, and insulin secretion. Reduces splanchnic blood flow and inhibits secretion of gastrointestinal hormones.
Subcutaneous: 50-100 mcg every 8-12 hours. Intravenous bolus: 50 mcg, then continuous infusion 25-100 mcg/hour for acute variceal bleeding.
Octreotide acetate 20 mg intramuscularly every 4 weeks for acromegaly; 20 mg intramuscularly every 4 weeks for neuroendocrine tumors; may initiate at 10 mg for symptom control of carcinoid syndrome and dose titrate based on response.
None Documented
None Documented
Terminal elimination half-life: 1.7–1.9 hours (subcutaneous); prolonged in hepatic impairment (up to 2.6 h). After intravenous bolus, biphasic elimination with t½ α ~0.2 h and t½ β ~1.5 h.
Terminal half-life: 12-14 days for subcutaneous octreotide LAR microspheres; clinical steady state achieved after 2-3 injections.
Renal: ~32% unchanged; biliary/fecal: ~66% as metabolites; total clearance ~160 mL/min.
Renal: 32% as unchanged drug; biliary/fecal: 60-70% via feces as metabolites and unchanged drug.
Category C
Category C
Somatostatin Analog
Somatostatin Analog